Icahn School of Medicine at Mount Sinai

 

Yale Cancer Center
Avatar

Myeloma in 2023: So Many Drugs, Yet So Few Cures

By Yale Cancer Center FEATURING Ajai Chari
By Yale Cancer Center FEATURING Ajai Chari
0 views
May 9, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

07:37
UCB, Inc.

Taking the Next Steps with a Nasal Rescue Treatment

Feat. D. Burdette

Featured Video

04:14
UCB, Inc.

Advances in Acute Seizure Treatment Options

Feat. L. Hirsch
Videos
16:56
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Sequencing Immunotherapy for Myeloma"

Feat. S. Parekh
05:26
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Indirect Comparison of Linvoseltamab Vs. …

Feat. S. Jagannath
16:52
Icahn School of Medicine at Mount Sinai

Navigating aGVHD Treatment: Integrating Recent Updates in Clinical M…

Feat. J. Ferrara
11:32
Icahn School of Medicine at Mount Sinai

Leveraging Liquid Biopsy in Lung Cancer

Feat. C. Rolfo
16:31
Icahn School of Medicine at Mount Sinai

PanRAF Inhibitors in NSCLC

Feat. R. Veluswamy
15:16
Icahn School of Medicine at Mount Sinai

AACR 2024 Insights: "Linvoseltamab, a BCMA-Targeted BsAb, in Pt…

Feat. S. Jagannath
21:52
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…

Feat. D. Tremblay
10:06
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Outcomes After CAR-T in MM Patients With Ex…

Feat. D. Pan
06:14
Insights from 2023 ASH Annual Meeting

Multiple Myeloma: Inflammatory Biomarkers and Outcomes CAR T-Cell Th…

Feat. D. Pan
03:14
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MyDRUG Sub-Protocol Y3 Results - Selinexor,…

Feat. J. Richter
06:51
Insights from 2023 ASH Annual Meeting

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Feat. D. Tremblay
10:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax Improves Response Rates But Not …

Feat. D. Tremblay
03:17
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Highlights From the International Myeloma S…

Feat. J. Richter
15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
44:42
Icahn School of Medicine at Mount Sinai

Managing the Nonreproductive Comorbidities of Polycycstic Ovary Synd…

Feat. A. Dunaif
04:34
Icahn School of Medicine at Mount Sinai

Revisiting the Role of Alkylating Agents in Myeloma: Up-to-Date Evid…

Feat. J. Richter
24:39
Icahn School of Medicine at Mount Sinai

Multiple Myeloma: Adverse Effects of CAR-T

Feat. S. Rajeeve
33:05
Icahn School of Medicine at Mount Sinai

Leveraging SCLC Subtypes and Other Biomarkers

Feat. F. Hirsch
52:39
Yale Cancer Center

Myeloma in 2023: So Many Drugs, Yet So Few Cures

Feat. A. Chari
10:46
Icahn School of Medicine at Mount Sinai

Overview of JAKARTA & JAKARTA2 Trials: Impact of Fedratinib on S…

Feat. J. Waksal
09:47
Icahn School of Medicine at Mount Sinai

What's the Difference? Covalent vs. Non-Covalent BTKis in MCL

Feat. J. Brody
15:31
Icahn School of Medicine at Mount Sinai

Myelofibrosis Treatment Options Beyond the JAK/STAT Pathway

Feat. M. Kremyanskaya
23:07
Icahn School of Medicine at Mount Sinai

Kidney Week 2022: Cell-to-Cell Chats in the Diabetic Kidney Endothel…

Feat. I. Daehn
12:43
Oliver Van Oekelen

Outcomes of MM Pts Progressing After BCMA-Targeted CAR T-Cell Therapy

14:03
ASH 2022 Conference Coverage

ASH 2022 Neurotoxicity With Motor Symptoms After BCMA-Directed CAR-T…

Feat. S. Parekh
09:13
SABCS 2022 Conference Coverage

SABCS 2022 Predictors of Response to Neoadjuvant Chemo in Breast Can…

Feat. N. Bilani
05:07
Icahn School of Medicine at Mount Sinai

TKI in the Management of Advanced HCC

Feat. A. Villanueva
11:42
Icahn School of Medicine at Mount Sinai

Symptom Assessments in Myelofibrosis and How to Examine the Spleen

Feat. M. Kremyanskaya
25:49
Icahn School of Medicine at Mount Sinai

Triplet Regimens in Early Relapse MM: Evolving Treatment Dynamics

Feat. C. Rodriguez